# **Costs of adverse event management associated** with first-line cetuximab or panitumumab in metastatic colorectal cancer patients in Algeria


Saïd Belhadef<sup>1</sup>, Hassen Mahfouf<sup>1</sup>, Mohammed Oukkal<sup>2</sup>, Salim Lamoudi<sup>3</sup>, Khaoula Chargui<sup>3</sup>, Chris P. Pescott<sup>4</sup>

<sup>1</sup>CHU Rouiba, Algeria; <sup>2</sup>CHU BéniMessous, Algeria; <sup>3</sup>Merck SARL, Tunis, Tunisia, an affiliate of Merck KGaA, Darmstadt, Germany; <sup>4</sup>Merck Healthcare KGaA, Darmstadt, Germany



#### **GET POSTER PDF**

Copies of this poster obtained through Quick Response (QR) Code are for personal use only and may not be reproduced without permission from SAFRO and the author of this poster.





 In Algeria, patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) can be treated with epidermal growth factor receptor (EGFR) monoclonal antibodies cetuximab (CET) or panitumumab (PAN) in combination with chemotherapy (CT)<sup>1</sup>



• A total of 2677 patients were estimated to be eligible for anti-EGFR therapy in 2020; of these, 46% received PAN+CT

- Cetuximab, an IgG1 monoclonal antibody, is indicated for the treatment of *RAS* wt mCRC in combination with irinotecan-based CT in any line, as first-line (1L) in combination with FOLFIRI or FOLFOX, and as a monotherapy in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan<sup>2</sup>
- Panitumumab, an IgG2 monoclonal antibody, is indicated for the treatment of *RAS* wt mCRC in 1L combination with FOLFOX or FOLFIRI, in second-line combination with FOLFIRI in patients who have received 1L fluoropyrimidinebased CT (excluding irinotecan), and as a monotherapy after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing CT regimens<sup>3</sup>
- In addition, rechallenge with anti-EGFR therapy is a valuable third-line treatment strategy for patients with mCRC<sup>4,5</sup>
- A clinician's choice of an anti-EGFR as a 1L treatment will be based on various factors, including adverse events (AEs)
- The costs associated with managing AEs varies depending on the AE profile of an anti-EGFR therapy. The financial impact of AE management costs on Algeria's national health fund has not been studied

OBJECTIVE

**METHODS** 


 To estimate the financial impact of AE management costs associated with CET+CT vs PAN+CT therapies on Algeria's national health fund using a country-specific cost model  In patients receiving CET+CT, all-grade AEs were estimated to be 58.1% lower and Grade 3/4 AEs were estimated to be 70.2% lower than in those receiving PAN+CT (Table 1)

### Table 1. Estimated frequency of AEs in patients with mCRC receiving CET+CT or PAN+CT

Number of AEs	All grade AEs		Grade 3/4 AEs	
Nullider of AES	CET+CT	PAN+CT	CET+CT	PAN+CT
Blood & lymphatic system disorders	-	206	-	194
Cardiovascular diseases	-	94	-	94
Eye disorders	19	318	5	99
Gastrointestinal disorders	37	1029	9	197
General disorders & administration site AEs	598	972	129	318
Hepatobiliary disorders	187	-	47	-
Immune system disorders	-	19	-	6
Infections & infestations	187	281	47	88
Metabolism & nutrition disorders	243	636	44	144
Musculoskeletal & connective tissue disorders	-	206	-	64
Nervous system disorders	19	243	5	76
Respiratory, thoracic & mediastinal disorders	187	411	47	129
Skin disorders	972	1440	184	326
AE total frequency	2450	5853	516	1734
Difference (CET+CT vs PAN+CT)	3403 (58.1%)		1218 (70.2%)	

- The average per-patient cost of managing all-grade AEs with CET+CT was 488 136 DZD lower than with PAN+CT. When considering grade 3/4 AEs, the average per-patient cost was 285 989 DZD lower with CET+CT than PAN+CT (**Figure 1**)
- The annual AE management cost for total eligible population with mCRC was ~166 million DZD lower with CET+CT versus PAN+CT; for grade 3/4 AEs, the annual cost saving was ~97 million DZD (Figure 2)


## Figure 1. Average per-patient costs of AE management in patients with mCRC receiving CET+CT or PAN+CT





- A model was developed to estimate the costs of AE management associated with 1L CET+CT and PAN+CT regimens based on AE frequency and severity. Costs were estimated based on expenses incurred by patients without reimbursement
- The frequencies of common and very common AEs were sourced from the Summaries of Product Characteristics<sup>2,3</sup>
- The severity of AEs was determined based on the meta-analysis by Petrelli et al. (2018)<sup>6</sup> which provides evidence on the frequency of all-grade and grade 3/4 AEs associated with CET+CT and PAN+CT
- The number of patients receiving each anti-EGFR therapy in Algeria was derived from global and local databases and market share data
- Base case (inpatient resource use and costs) were based on the Diagnosis Related Groups (DRGs) and derived from the average number and cost of hospitalizations reported in literature sources
- A sensitivity analysis was conducted using the upper and lower limits of the AE frequency definitions (i.e., very common ≥1/10, common ≥1/100 to <1/10)</li>
- The model inputs and results were validated by Algerian physicians who specialize in treating mCRC and use both CET+CT and PAN+CT as treatment options

#### Figure 2. Average annual costs of AE management for total eligible mCRC population receiving CET+CT or PAN+CT



 When using the lower and upper limits of the AE frequency definitions, average savings per patient treated with CET+CT ranged from 88 752 DZD to 887 520 DZD (Table 2)

#### Table 2. Sensitivity analysis – cost for treating all grade AEsusing minimum and maximum AE frequencies

Per-patient inpatient costs (all grade AEs), DZD	CET+CT	PAN+CT	Difference
Minimum AE frequency	17 569	106 321	88 752
Median AE frequency	96 629	584 765	488 136
Maximum AE frequency	175 689	1 063 209	887 520

This analysis was financially supported by Merck SARL, Tunis, Tunisia, an affiliate of Merck KGaA (CrossRef Funder ID: 10.13039/100009945).

**ABBREVIATIONS:** 1L, first-line; AE, adverse event; CET, cetuximab; CT, chemotherapy; DRGs, Diagnosis Related Groups; EGFR, epidermal growth factor receptor; FOLFOX, folinic acid, fluorouracil and oxaliplatin; FOLFIRI, folinic acid, fluorouracil and irinotecan; mCRC, metastatic colorectal cancer; PAN, panitumumab; wt, wild-type.

**REFERENCES: 1.** République Algérienne Démocratique et Populaire Ministère de la santé. Guides Thérapeutiques en Oncologie Médicale Année 2022. Available at: http://www.safro-dz.org/media/attachments/2022/06/28/guides-thrapeutiques-en-oncologie-mdicale-2022-v9.pdf. Accessed: 7 November 2022; **2.** European Medicines Agency. Erbitux Summary of Product Characteristics (SmPC). 2022. Available at: https://www.ema.europa.eu/en/documents/product-information/erbitux-epar-product-information\_en.pdf. Accessed: 7 November 2022; **3.** European Medicines Agency. Vectibix Summary of Product Characteristics (SmPC). 2022. Available at:

https://www.ema.europa.eu/en/documents/product-information/vectibix-epar-product-information\_en.pdf. Accessed: 7 November 2022; **4.** Cremolini C, *et al. JAMA Oncol.* 2019; 5(3):343–350;

5. Martinelli E, et al. JAMA Oncol. 2021; 7(10):1529–1535; 6. Petrelli F, et al. Oncology. 2018; 94(4):191–199.

**DISCLOSURES:** SL and KC are employees of Merck SARL. CPP is an employee of Merck KGaA. Medical writing assistance (funded by Merck KGaA, Darmstadt, Germany) was provided by ClinicalThinking, Inc, Hamilton, NJ, USA.

CORRESPONDENCE: Saïd Belhadef Email: sbelhadef@yahoo.fr